THE DEAL, AT A GLANCE
2/4 reviewedNanomerics
01What it doesNanomerics makes nanoparticle drug-delivery systems for eye, brain and gene medicines.Source-grounded · automated review · Explore ↗
02Who is involvedBacked by a German strategic investor, with the Silverstein DreamFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedNanomerics raised Series A, announced 2026-09-29From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersIts technology aims to help medicines reach disease sites despite biological delivery barriers.Interpretation · Explore ↗
Checked 2026-10-05 · Review due 2026-10-12
Read supporting source ↗An award-winning Active Excipient platform…
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Nanomerics · Financing Record
Explore source-linked visual explanations for Nanomerics. Unsupported claims are withheld while source review continues.
Record 13087 · Recorded date: 2026-09-29
Explore company records →